Two men wearing climbing gear stand on a mountain ledge and look out over the mountain landscape.

For adults with hypercholesterolemia, including those with HeFH, who still aren't at target

Lower your patients' LDL-C to their target and keep it there,
the LEROCHOL way.

Robust and sustained LDL-C lowering that's designed for
long-term treatment^1–3*

Clinical Efficacy & Safety

See how LEROCHOL delivered LDL-C reduction across a broad range of patients^1,3,4

View clinical data

Autoinjector
coming soon

How To Get LEROCHOL

Prefilled syringe available through LEROCHOL Direct™ with a prescription

Get the details

Mechanism of Action

Learn about the
MOA for LEROCHOL

See how LEROCHOL works

Video still of a man and woman sitting at a small round table in conversation.

"Every patient is different, but the goal is always the same. Get your LDL-C all the way down to target and keep it there."

–Evan Stein, MD, PhD, FACC; Chief Executive and Scientific Officer of LIB Therapeutics, Inc.

Video features a conversation between Dr. Stein and Adriane where they discuss her journey finding the right LDL-C-lowering treatment for her needs. Adriane is a real patient and was compensated for her time.

HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9 inhibitor. *Indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH.² ^†Store refrigerated at 2°C to 8°C (36°F to 46°F). LEROCHOL may be kept at room temperature up to 25°C (77°F) in the original carton and must be used within 3 months of being removed from the refrigerator. If not used within 3 months, discard LEROCHOL.²

References: 1. Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800-807. 2. Lerochol [prescribing information]. LIB Therapeutics; 2026. 3. Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272-4280. 4. Kereiakes DJ Fourie N, Engelbrecht J, et al. Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease. Atherosclerosis. 2024;395(suppl 1):118465.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most commonly occurring adverse reactions in clinical trials in primary hyperlipidemia in adults (including heterozygous familial hypercholesterolemia [HeFH]) ≥2% of patients treated with LEROCHOL^® (lerodalcibep-liga) and occurring more frequently than with placebo were nasopharyngitis (15% and 14% versus placebo), local injection site reactions (12% and 5% versus placebo) and peripheral edema (2% and <1% versus placebo).

The most commonly occurring adverse reactions in clinical trials in HeFH (≥2% of patients treated with LEROCHOL and occurring more frequently than with placebo) were injection site reactions (18% and 3% versus placebo), nasopharyngitis (13% and 9% versus placebo), diarrhea (3% and 1% versus placebo), nausea (2% and 0% versus placebo) and peripheral edema (2% and <1% versus placebo).

The most frequent adverse reaction leading to treatment discontinuation in trials in primary hypercholesterolemia in adults was injection site reactions, with a higher frequency in the LEROCHOL-treated group compared to placebo-treated patients (1% versus 0%).

Immunogenicity

LEROCHOL is a recombinant fusion protein. As with all therapeutic proteins, there is potential for immunogenicity with LEROCHOL.

INDICATIONS

LEROCHOL^® (lerodalcibep-liga) is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

Cardiovascular outcomes trials have demonstrated that reducing LDL‑C lowers the risk for major adverse cardiovascular events (MACE) in adults at increased risk when treated with statins or monoclonal antibody PCSK9 inhibitors as an add-on to statin therapy.

IMPORTANT SAFETY INFORMATION

Adverse Reactions

INDICATIONS

Lower your patients' LDL-C to their target and keep it there, the LEROCHOL way.

Clinical Efficacy & Safety

How To Get LEROCHOL

Mechanism of Action

IMPORTANT SAFETY INFORMATION

Adverse Reactions

Immunogenicity

INDICATIONS

Lower your patients' LDL-C to their target and keep it there,
the LEROCHOL way.